| [1] |
Marcucci G，Metzeler KH，Schwind S，et al.Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia[J].J Clin Oncol，2012，30（7）：742-750.
|
| [2] |
Pemmaraju N，Kantarjian H，Andreeff M，et al.Investigational FMS-like tyrosine kinase3 inhibitors in treatment of acute myeloid leukemia[J].Expert Opin Investig Drugs，2014，23（7）：943-954.
|
| [3] |
Govedarovic N，Marjanovic G.Frequency and prognostic impact of FLT3-ITD mutation in patients with acute myeloid leukemia[J].J BUON，2011，16（1）：108-111.
|
| [4] |
Yang L，Rau R，Goodell MA，et al.DNMT3A in haematological malignancies[J].Nature Reviews Cancer，2015，15（3）：152-165.
|
| [5] |
Holz-Schietinger C，Matje DM，Reich NO，et al.Mutations in DNAmethyltransferase（DNMT3A）observed in acute myeloid leukemia patients disrupt processive methylation[J].J Biol Chem，2012，287（37）：30941-30951.
|
| [6] |
Russler-GermainDA，SpencerDH，YoungMA，etal.TheR882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers[J].Cancer Cell，2014，25（4）：442-454.
|
| [7] |
Brunetti L，Gundry MC，Goodell MA，et al.DNMT3A in Leukemia[J].Cold Spring Harb Perspect Med，2017，7（2）：303-320.
|
| [8] |
Kim SJ，Zhao H，Hardikar S，et al.ADNMT3A mutation com-mon in AML exhibits dominant-negative effects in murine ES cells[J].Blood，2013，122（25）：4086-4089.
|
| [9] |
Mayle A，Yang L，Rodriguez B，et al.Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation[J].Blood，2015，125（4）：629-638.
|
| [10] |
Vogelstein B，Papadopoulos N，Velculescu VE，et al.Cancer genome landscapes[J].Science，2013，339（24）：1546-1558.
|
| [23] |
中华医学会血液学分会.急性髓系白血病（复发难治性）中国诊疗指南[J].中华血液学杂志，2011，32（12）：887-888.
|
| [11] |
Yang L，Rodriguez B，Luo M，et al.Dnmt3a-deletion accelerates FLT3-ITD malignancies in mice by hypomethylation of enhancer sites and activating stem cell programs;implications for therapy[J].Blood，2013，122（2）：21-59.
|
| [12] |
Guryanova OA，Lieu YK，Garrett-Bakelman FE，et al.Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells[J].Leukemia，2016，30（5）： 1133-1142.
|
| [13] |
Meyer SE，Qin T，Muench DE，et al.DNMT3A haploinsufficiency transforms FLT3-ITD myeloproliferative disease into a rapid，spontaneous，and fully penetrant acute myeloid leukemia[J].Cancer Discov，2016，6（5）：501-515.
|
| [14] |
Yang L，Rodriguez B，Mayle A，et al.DNMT3A loss drives enhancer hypomethylation in FLT3-ITD associated leukemias[J].Cancer Cell，2016，29（6）：922-934.
|
| [15] |
Poitras JL，Heiser D，Li L，et al.Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model[J].Oncotarget，2016，7（43）：69124-69135.
|
| [16] |
Tang S，Shen H，Wu D，et al.FLT3-ITD with DNMT3A R882 doublemutationisapoorprognosticfactorinChinesepatients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation[J].Int J Hematol，2017，106（4）：552-561.
|
| [17] |
Ahn JS，Kim HJ，Kim YK，et al.DNMT3A R882 mutation with FLT3-ITD positivity is an extremely poor prognostic factor in patients with normal-karyotype acute myeloid leukemia after allogeneic hematopoietic cell transplantation[J].Biol Blood Marrow Transplant，2016，22（1）：61-70.
|
| [18] |
Gaidzik VI，Schlenk RF，Paschka P，et al.Clinical impact of DNMT3A mutations in younger adult patients with acute myeloidleukemia：resultsoftheAMLStudyGroup（AMLSG）[J].Blood，2013，121（23）：4769-4777.
|
| [19] |
Gale RE，Lamb K，Allen C，et al.Simpson′s paradox and the impactofdifferentDNMT3Amutationsonoutcomeinyounger adults with acute myeloid leukemia[J].J Clin Oncol，2015，33（18）：2072-2083.
|
| [20] |
Renneville A，Boissel N，Nibourel O，et al.Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia：a study by the Acute Leukemia French Association[J].Leukemia，2012，26（6）：1247-1254.
|
| [21] |
Hou HA，Kuo YY，Liu CY，et al.DNMT3A mutations in acute myeloid leukemia：stability during disease evolution and clinical implications[J].Blood，2012，119（2）：559-568.
|
| [22] |
Kronke J，Bullinger L，Teleanu V，et al.Clonal evolution in relapsed NPM1 mutated acute myeloid leukemia[J].Blood，2013，122（1）：100-108.
|
| [24] |
O′Donnell MR，Tallman MS，Abboud CN，et al.Acute Myeloid Leukemia，Version 3.2017，NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw，2017，15（7）：926-957.
|
| [25] |
Tian H，Xu Y，Liu L，et al.Comparison of outcomes in mixed phenotypeacuteleukemiapatientstreatedwithchemotherapy and stem cell transplantation versus chemotherapy alone[J].Leuk Res，2016，45：40-46.
|
